Cargando…

Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis

BACKGROUND: Glioblastoma multiforme (GBM) is characterized by an unfavorable prognosis for patients affected. During standard-of-care chemotherapy using temozolomide (TMZ), tumors acquire resistance thereby causing tumor recurrence. Thus, deciphering essential molecular pathways causing TMZ resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Stillger, Maren Nicole, Chen, Chia-Yi, Lai, Zon Weng, Li, Mujia, Schäfer, Agnes, Pagenstecher, Axel, Nimsky, Christopher, Bartsch, Jörg Walter, Schilling, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022304/
https://www.ncbi.nlm.nih.gov/pubmed/36932402
http://dx.doi.org/10.1186/s12935-023-02889-8
_version_ 1784908701652484096
author Stillger, Maren Nicole
Chen, Chia-Yi
Lai, Zon Weng
Li, Mujia
Schäfer, Agnes
Pagenstecher, Axel
Nimsky, Christopher
Bartsch, Jörg Walter
Schilling, Oliver
author_facet Stillger, Maren Nicole
Chen, Chia-Yi
Lai, Zon Weng
Li, Mujia
Schäfer, Agnes
Pagenstecher, Axel
Nimsky, Christopher
Bartsch, Jörg Walter
Schilling, Oliver
author_sort Stillger, Maren Nicole
collection PubMed
description BACKGROUND: Glioblastoma multiforme (GBM) is characterized by an unfavorable prognosis for patients affected. During standard-of-care chemotherapy using temozolomide (TMZ), tumors acquire resistance thereby causing tumor recurrence. Thus, deciphering essential molecular pathways causing TMZ resistance are of high therapeutic relevance. METHODS: Mass spectrometry based proteomics were used to study the GBM proteome. Immunohistochemistry staining of human GBM tissue for either calpain-1 or -2 was performed to locate expression of proteases. In vitro cell based assays were used to measure cell viability and survival of primary patient-derived GBM cells and established GBM cell lines after TMZ ± calpain inhibitor administration. shRNA expression knockdowns of either calpain-1 or calpain-2 were generated to study TMZ sensitivity of the specific subunits. The Comet assay and ɣH2AX signal measurements were performed in order to assess the DNA damage amount and recognition. Finally, quantitative real-time PCR of target proteins was applied to differentiate between transcriptional and post-translational regulation. RESULTS: Calcium-dependent calpain proteases, in particular calpain-2, are more abundant in glioblastoma compared to normal brain and increased in patient-matched initial and recurrent glioblastomas. On the cellular level, pharmacological calpain inhibition increased the sensitivities of primary glioblastoma cells towards TMZ. A genetic knockdown of calpain-2 in U251 cells led to increased caspase-3 cleavage and sensitivity to neocarzinostatin, which rapidly induces DNA strand breakage. We hypothesize that calpain-2 causes desensitization of tumor cells against TMZ by preventing strong DNA damage and subsequent apoptosis via post-translational TP53 inhibition. Indeed, proteomic comparison of U251 control vs. U251 calpain-2 knockdown cells highlights perturbed levels of numerous proteins involved in DNA damage response and downstream pathways affecting TP53 and NF-κB signaling. TP53 showed increased protein abundance, but no transcriptional regulation. CONCLUSION: TMZ-induced cell death in the presence of calpain-2 expression appears to favor DNA repair and promote cell survival. We conclude from our experiments that calpain-2 expression represents a proteomic mode that is associated with higher resistance via “priming” GBM cells to TMZ chemotherapy. Thus, calpain-2 could serve as a prognostic factor for GBM outcome. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-023-02889-8.
format Online
Article
Text
id pubmed-10022304
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100223042023-03-18 Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis Stillger, Maren Nicole Chen, Chia-Yi Lai, Zon Weng Li, Mujia Schäfer, Agnes Pagenstecher, Axel Nimsky, Christopher Bartsch, Jörg Walter Schilling, Oliver Cancer Cell Int Research BACKGROUND: Glioblastoma multiforme (GBM) is characterized by an unfavorable prognosis for patients affected. During standard-of-care chemotherapy using temozolomide (TMZ), tumors acquire resistance thereby causing tumor recurrence. Thus, deciphering essential molecular pathways causing TMZ resistance are of high therapeutic relevance. METHODS: Mass spectrometry based proteomics were used to study the GBM proteome. Immunohistochemistry staining of human GBM tissue for either calpain-1 or -2 was performed to locate expression of proteases. In vitro cell based assays were used to measure cell viability and survival of primary patient-derived GBM cells and established GBM cell lines after TMZ ± calpain inhibitor administration. shRNA expression knockdowns of either calpain-1 or calpain-2 were generated to study TMZ sensitivity of the specific subunits. The Comet assay and ɣH2AX signal measurements were performed in order to assess the DNA damage amount and recognition. Finally, quantitative real-time PCR of target proteins was applied to differentiate between transcriptional and post-translational regulation. RESULTS: Calcium-dependent calpain proteases, in particular calpain-2, are more abundant in glioblastoma compared to normal brain and increased in patient-matched initial and recurrent glioblastomas. On the cellular level, pharmacological calpain inhibition increased the sensitivities of primary glioblastoma cells towards TMZ. A genetic knockdown of calpain-2 in U251 cells led to increased caspase-3 cleavage and sensitivity to neocarzinostatin, which rapidly induces DNA strand breakage. We hypothesize that calpain-2 causes desensitization of tumor cells against TMZ by preventing strong DNA damage and subsequent apoptosis via post-translational TP53 inhibition. Indeed, proteomic comparison of U251 control vs. U251 calpain-2 knockdown cells highlights perturbed levels of numerous proteins involved in DNA damage response and downstream pathways affecting TP53 and NF-κB signaling. TP53 showed increased protein abundance, but no transcriptional regulation. CONCLUSION: TMZ-induced cell death in the presence of calpain-2 expression appears to favor DNA repair and promote cell survival. We conclude from our experiments that calpain-2 expression represents a proteomic mode that is associated with higher resistance via “priming” GBM cells to TMZ chemotherapy. Thus, calpain-2 could serve as a prognostic factor for GBM outcome. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-023-02889-8. BioMed Central 2023-03-17 /pmc/articles/PMC10022304/ /pubmed/36932402 http://dx.doi.org/10.1186/s12935-023-02889-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Stillger, Maren Nicole
Chen, Chia-Yi
Lai, Zon Weng
Li, Mujia
Schäfer, Agnes
Pagenstecher, Axel
Nimsky, Christopher
Bartsch, Jörg Walter
Schilling, Oliver
Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis
title Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis
title_full Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis
title_fullStr Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis
title_full_unstemmed Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis
title_short Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis
title_sort changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing dna damage and p53-dependent apoptosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022304/
https://www.ncbi.nlm.nih.gov/pubmed/36932402
http://dx.doi.org/10.1186/s12935-023-02889-8
work_keys_str_mv AT stillgermarennicole changesincalpain2expressionduringglioblastomaprogressionpredisposestumorcellstotemozolomideresistancebyminimizingdnadamageandp53dependentapoptosis
AT chenchiayi changesincalpain2expressionduringglioblastomaprogressionpredisposestumorcellstotemozolomideresistancebyminimizingdnadamageandp53dependentapoptosis
AT laizonweng changesincalpain2expressionduringglioblastomaprogressionpredisposestumorcellstotemozolomideresistancebyminimizingdnadamageandp53dependentapoptosis
AT limujia changesincalpain2expressionduringglioblastomaprogressionpredisposestumorcellstotemozolomideresistancebyminimizingdnadamageandp53dependentapoptosis
AT schaferagnes changesincalpain2expressionduringglioblastomaprogressionpredisposestumorcellstotemozolomideresistancebyminimizingdnadamageandp53dependentapoptosis
AT pagenstecheraxel changesincalpain2expressionduringglioblastomaprogressionpredisposestumorcellstotemozolomideresistancebyminimizingdnadamageandp53dependentapoptosis
AT nimskychristopher changesincalpain2expressionduringglioblastomaprogressionpredisposestumorcellstotemozolomideresistancebyminimizingdnadamageandp53dependentapoptosis
AT bartschjorgwalter changesincalpain2expressionduringglioblastomaprogressionpredisposestumorcellstotemozolomideresistancebyminimizingdnadamageandp53dependentapoptosis
AT schillingoliver changesincalpain2expressionduringglioblastomaprogressionpredisposestumorcellstotemozolomideresistancebyminimizingdnadamageandp53dependentapoptosis